Cargando…

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate

BACKGROUND: Chronic bronchitis (CB) is one of the conditions that contribute to chronic obstructive pulmonary disease (COPD). Despite its widespread prevalence among patients with COPD and overall negative impact on treatment outcomes, the effect of CB on the efficacy of bronchodilator therapy has n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tashkin, Donald P, Ozol-Godfrey, Ayca, Sharma, Sanjay, Sanjar, Shahin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051958/ https://www.ncbi.nlm.nih.gov/pubmed/33880019 http://dx.doi.org/10.2147/COPD.S304182

Ejemplares similares

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
por: Putcha, Nirupama, et al.
Publicado: (2021)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Ohar, Jill A, et al.
Publicado: (2020)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
por: Donohue, James F, et al.
Publicado: (2020)

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
por: Hanania, Nicola A, et al.
Publicado: (2021)

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies
por: Tashkin, Donald P., et al.
Publicado: (2019)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
por: Siler, Thomas M., et al.
Publicado: (2021)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
por: Ohar, Jill A, et al.
Publicado: (2019)

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
por: Ohar, Jill, et al.
Publicado: (2018)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
por: Ohar, Jill A., et al.
Publicado: (2020)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Publicado: (2021)

A review of nebulized drug delivery in COPD
por: Tashkin, Donald P
Publicado: (2016)

CAT Score and SGRQ Definitions of Chronic Bronchitis as an Alternative to the Classical Definition
por: Choi, Joon Young, et al.
Publicado: (2019)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]
Publicado: (2020)

An empirical comparison of the WHOQOL-BREF and the SGRQ among patients with COPD
por: Liang, Wen-Miin, et al.
Publicado: (2008)

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018)

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease
por: Leaker, Brian R, et al.
Publicado: (2015)

The use of nebulized pharmacotherapies during the COVID-19 pandemic
por: Sethi, Sanjay, et al.
Publicado: (2020)

Understanding and measuring symptoms and health status in asthma COPD overlap: content validity of the EXACT and SGRQ
por: Nelsen, Linda, et al.
Publicado: (2018)

Health status of COPD patients undergoing pulmonary rehabilitation: A comparative responsiveness of the CAT and SGRQ
por: Sciriha, Anabel, et al.
Publicado: (2017)

Are in Person and Telephone Interviews Equivalent Modes of Administrating the CAT, the FACIT-FS and the SGRQ in People With COPD?
por: Rocha, Vânia, et al.
Publicado: (2021)

Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease
por: Leaker, Brian R., et al.
Publicado: (2019)

Validation and clinical interpretation of the St George’s respiratory questionnaire for COPD (SGRQ-C) after adaptation to Malaysian language and culture, in patients with COPD
por: Rehman, Anees ur, et al.
Publicado: (2020)

Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
por: Donohue, James F., et al.
Publicado: (2017)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ
por: Menn, Petra, et al.
Publicado: (2010)

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Glycopyrrolate in toxic exposure to ammonia gas
por: Bhalla, A, et al.
Publicado: (2011)

Using the Three-Step Test Interview to understand how patients perceive the St. George’s Respiratory Questionnaire for COPD patients (SGRQ-C)
por: Paap, Muirne C. S., et al.
Publicado: (2015)

Is nebulized saline a placebo in COPD?
por: Khan, Shahina Y, et al.
Publicado: (2004)

Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
por: Ganapathy, Vaidyanathan, et al.
Publicado: (2017)

Management of plastic bronchitis with nebulized tissue plasminogen activator: another brick in the wall
por: Colaneri, Massimo, et al.
Publicado: (2014)

Nebulized corticosteroids in the management of acute exacerbation of COPD
por: Gaude, G. S., et al.
Publicado: (2010)

Effectiveness of treatment with nebulized colistin in patients with COPD
por: Bruguera-Avila, Nuria, et al.
Publicado: (2017)

Nebulized Therapies in COPD: Past, Present, and the Future
por: Barjaktarevic, Igor Z, et al.
Publicado: (2020)

Comparative analysis of the psychometric parameters of two quality-of-life questionnaires, the SGRQ and CAT, in the assessment of patients with COPD exacerbations during hospitalization: A multicenter study
por: Folch Ayora, Ana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ujo18da2skl7e816432s90i32o